# A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

> **NCT06973720** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Metsera, a wholly owned subsidiary of Pfizer** · enrollment: 268 (actual)

## Conditions studied

- Obesity
- Overweight or Obesity

## Interventions

- **DRUG:** MET097
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06973720
- **Lead sponsor:** Metsera, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2025-12-16
- **Final completion:** 2026-10-16
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973720, "A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06973720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*